NEW
YORK, May 1, 2024 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical
company, today announced that Robb
Knie, Chief Executive Officer, is scheduled to attend
the EF Hutton Annual Global Conference in New York, NY.
To learn more about the EF Hutton Annual Global Conference
please visit https://efhutton.com/conference/.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a
clinical-stage biopharmaceutical company dedicated to
developing innovative, impactful, and ground-breaking
treatments with a goal to improve patient quality of life. We are a
catalyst in early-stage pharmaceutical research and development,
elevating drugs from the bench to pre-clinical and clinical
testing. Utilizing a patient-centric approach, we collaborate and
partner with a team of scientists, clinicians, and key opinion
leaders to seek out and investigate therapeutics that hold
immense potential to create breakthroughs and diversify
treatment options. To learn more, please visit
https://ir.hoththerapeutics.com/ .
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-to-attend-ef-hutton-annual-global-conference-may-15-2024-302132803.html
SOURCE Hoth Therapeutics, Inc.
